RARE CANCERBone CancerWHO 5th Edition Classification

Osteosarcoma

Rare Malignancy (< 6 cases per 100,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

The commonest primary bone cancer, arising from bone-forming cells. It typically develops in the growing ends of long bones - around the knee and in the upper arm - during the adolescent growth spurt. A second incidence peak occurs in older adults, often on a background of Paget disease or prior radiotherapy.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Night bone pain in a teenager - X-ray, do not just prescribe analgesia
  • Biopsy only at the treating sarcoma centre - a poorly placed tract can cost the limb
Who It Affects

Adolescents and young adults 10-20 years; second peak over 60; male predominance

Annual Incidence

Approximately 3-4 per million per year, higher during adolescence

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Deep bone pain, characteristically worse at night and not relieved by rest
Swelling or a lump over the affected bone
Reduced movement in the nearby joint, or a limp
A fracture through the weakened bone after minor injury
Pain often mistaken for a sports injury or growing pains for months

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

TP53 including germline (Li-Fraumeni)RB1 including hereditary retinoblastoma survivorsChromothripsis and high genomic instabilityMDM2/CDK4 in low-grade variants

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Neoadjuvant MAP chemotherapy - high-dose methotrexate, doxorubicin and cisplatin

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Limb-salvage surgery with endoprosthetic reconstruction wherever feasible

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Amputation or rotationplasty where limb salvage is not possible

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Adjuvant chemotherapy guided by the degree of tumour necrosis in the resected specimen

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Metastasectomy for resectable lung metastases, which can still be curative

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Five-year survival is approximately 60-70% for localised disease treated with combined chemotherapy and surgery, but roughly 20-30% with metastases at presentation. Good histological response to neoadjuvant chemotherapy is the strongest favourable prognostic factor. Outcomes have plateaued since the 1980s, which is the central problem in the field.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Trials of mifamurtide, immunotherapy, and agents targeting the genomically chaotic osteosarcoma genome continue; international collaboration through groups such as EURAMOS is essential given plateaued outcomes.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Osteosarcoma

Browse All Oncologists

Dr. Richard Gorlick

Division Head of Pediatrics, Director of Osteosarcoma Research Laboratory

25+ yrs exp

MD Anderson Cancer Center

Houston, USA

Pediatric OncologyOsteosarcomaOsteosarcoma Research
Vetted DirectoryConsult Specialist

Dr. Paul A. Meyers

Pediatric Oncologist

40+ yrs exp

MSKCC

New York, USA

Pediatric OncologyOsteosarcomaChemotherapy Protocols
Vetted DirectoryConsult Specialist

Dr. Kam Chan Hui

Pediatric Oncologist

15+ yrs exp

KKH

Singapore, Singapore

Pediatric OncologyOsteosarcomaMAP Chemotherapy
Vetted DirectoryConsult Specialist

Prof. Stefan Bielack

Pediatric Oncologist

30+ yrs exp

Olgahospital

Stuttgart, Germany

Pediatric OncologyOsteosarcomaCOSS Trials
Vetted DirectoryConsult Specialist

Dr. G. K. Prabhu

Orthopedic Oncologist

20+ yrs exp

HCG

Bengaluru, India

Orthopedic OncologyLimb-sparing SurgeryOsteosarcoma
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

rare

Cancer of Unknown Primary (CUP)

rare

Malignant Mesothelioma

rare

Retinoblastoma

rare

Ewing Sarcoma

Independent Tumor Board Review

Facing a Diagnosis of Osteosarcoma?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult